S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
These are the Top 4 Stocks for Buybacks in 2024
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
NASDAQ:IVA

Inventiva (IVA) Stock Price, News & Analysis

$3.31
+0.09 (+2.80%)
(As of 04/18/2024 ET)
Today's Range
$3.22
$3.47
50-Day Range
$3.22
$4.36
52-Week Range
$2.22
$5.05
Volume
11,854 shs
Average Volume
36,578 shs
Market Capitalization
$173.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Inventiva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
392.8% Upside
$17.00 Price Target
Short Interest
Healthy
0.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.23) to ($2.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.85 out of 5 stars

Medical Sector

601st out of 919 stocks

Pharmaceutical Preparations Industry

257th out of 405 stocks

IVA stock logo

About Inventiva Stock (NASDAQ:IVA)

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

IVA Stock Price History

IVA Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
INVENTIVA: Inventiva reports its 2023 full-year results
Inventiva reports its 2023 full-year results
See More Headlines
Receive IVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IVA
Fax
N/A
Employees
120
Year Founded
2011

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$25.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+418.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$18.91 million
Book Value
($0.67) per share

Miscellaneous

Free Float
35,684,000
Market Cap
$172.13 million
Optionable
Not Optionable
Beta
0.90

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Pierre Broqua Ph.D. (Age 62)
    Co-Founder, Chief Scientific Officer, Deputy CEO & Director
    Comp: $439.12k
  • Mr. Frederic Cren (Age 58)
    Co-Founder, CEO & Chairman
    Comp: $535.77k
  • Mr. Jean Volatier (Age 59)
    Deputy GM & CFO
  • Ms. Alice Roudot-Ketelers Pharm.D. (Age 53)
    Chief Operating Officer
  • Mr. Eric Duranson L.L.M. (Age 50)
    General Counsel
  • Ms. Nathalie Harroy (Age 57)
    Head of Human Resources
  • Dr. Michael Cooreman (Age 66)
    Chief Medical Officer
  • Ms. Pascaline Clerc Ph.D. (Age 44)
    Executive Vice President of Strategy & Corporate Affairs

IVA Stock Analysis - Frequently Asked Questions

Should I buy or sell Inventiva stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inventiva in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IVA shares.
View IVA analyst ratings
or view top-rated stocks.

What is Inventiva's stock price target for 2024?

8 equities research analysts have issued 12 month price objectives for Inventiva's shares. Their IVA share price targets range from $11.00 to $25.00. On average, they expect the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 392.8% from the stock's current price.
View analysts price targets for IVA
or view top-rated stocks among Wall Street analysts.

How have IVA shares performed in 2024?

Inventiva's stock was trading at $4.52 at the beginning of the year. Since then, IVA stock has decreased by 23.7% and is now trading at $3.45.
View the best growth stocks for 2024 here
.

Are investors shorting Inventiva?

Inventiva saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 57,600 shares, a decrease of 52.7% from the March 15th total of 121,900 shares. Based on an average daily volume of 39,400 shares, the days-to-cover ratio is currently 1.5 days.
View Inventiva's Short Interest
.

When did Inventiva IPO?

Inventiva (IVA) raised $103 million in an IPO on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers.

How do I buy shares of Inventiva?

Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners